ALUMIS INC. (ALMS) · INSIDERData sourcesSEC Form 450m ago
House PTR50m ago
SEC 13F50m ago
Robinhood Chain50m ago
Public companyALUMIS INC.
ALMSCIK 0001847367
Price$6.03
1 year+31.9%
Disclosed transactions11
Buys / sells0 / 6
Max Insider Score36
Connections with evidence8
ALMS · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 36 | BCBradley Mark ChristopherChief Development Officer | ALMSALUMIS INC. Open-market sale | SELL | $4,062 623 sh | Nov 2, 2026 | Nov 4, 2026 |
| 36 | PSPangali SanamChief Legal Officer | ALMSALUMIS INC. Open-market sale | SELL | $2,165 332 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 36 | SRSchroer John R.Chief Financial Officer | ALMSALUMIS INC. Open-market sale | SELL | $5,177 794 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 36 | HCHardiman Roy C.Chief Business & Strategy Ofcr | ALMSALUMIS INC. Open-market sale | SELL | $4,251 652 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 36 | DJDrappa JornChief Medical Officer | ALMSALUMIS INC. Open-market sale | SELL | $3,866 593 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 36 | GMGoldstein David MChief Scientific Officer | ALMSALUMIS INC. Open-market sale | SELL | $4,101 629 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 9 | PSPangali SanamChief Legal Officer | ALMSALUMIS INC. Grant or award | A | — 186.2K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 9 | SRSchroer John R.Chief Financial Officer | ALMSALUMIS INC. Grant or award | A | — 202.2K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 9 | GMGoldstein David MChief Scientific Officer | ALMSALUMIS INC. Grant or award | A | — 216.7K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 9 | DJDrappa JornChief Medical Officer | ALMSALUMIS INC. Grant or award | A | — 221.4K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
| 9 | BCBradley Mark ChristopherChief Development Officer | ALMSALUMIS INC. Grant or award | A | — 190.2K sh | Jan 26, 2026 | Jan 28, 2026 traded Jan 26, 2026 | +2d | SEC Form 4 | |
Chief Scientific Officer · Jan 28, 2026
Planned sales and 5% stakes
Form 144, 13D and 13G